Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells

Blood Cells Mol Dis. 2011 Dec 15;47(4):264-9. doi: 10.1016/j.bcmd.2011.08.004. Epub 2011 Sep 10.

Abstract

Resistance to chemotherapy and non-specific cytotoxicity are the major challenges to the treatment of acute myeloid leukemia (AML). In this study, we demonstrated that the disulfiram/copper (DS/Cu) complex alone exhibited cytotoxicity to doxorubicin (Dox) resistant leukemia HL60 cells (HL60/Dox) and enhanced cytotoxicity of Dox to HL60/Dox cells. DS/Cu inhibited Bcl-2 expression and enhanced Dox-induced apoptosis. DS/Cu/Dox in combination significantly induced c-Jun expression and JNK and c-Jun phosphorylation. JNK inhibitor Sp600125 attenuated DS/Cu/Dox-induced apoptosis and suppressed DS/Cu/Dox-induced protein expression in JNK/c-jun pathway. This study suggested that DS/Cu complex may re-sensitize HL60/Dox cells to Dox through activating JNK/c-jun as well as inhibiting anti-apoptotic bcl-2 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Copper / toxicity*
  • Disulfiram / toxicity*
  • Doxorubicin / toxicity*
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • HL-60 Cells
  • Humans
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Leukemia, Myeloid, Acute / enzymology*
  • MAP Kinase Signaling System / drug effects*
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-jun / metabolism*

Substances

  • Proto-Oncogene Proteins c-jun
  • Copper
  • Doxorubicin
  • JNK Mitogen-Activated Protein Kinases
  • Disulfiram